MicroRNA and mRNA expression profiling in metastatic melanoma reveal associations with BRAF mutation and patient prognosis

Pigment Cell and Melanoma Research

Volumn 28, Issue 3, 2015, Pages 254-266

  Tembe, Varsha ^a   Schramm, Sarah Jane ^a   Stark, Mitchell S ^b,c   Patrick, Ellis ^a   Jayaswal, Vivek ^a   Tang, Yue Hang ^d   Barbour, Andrew ^d   Hayward, Nicholas K ^b   Thompson, John F ^a,e   Scolyer, Richard A ^a,e,f   Yang, Yee Hwa ^a   Mann, Graham J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

BRAF; Bioinformatics; Biomarker; Melanoma; MicroRNA; MiRNA; Network; Pathology; Prognosis

Indexed keywords

B RAF KINASE; MESSENGER RNA; MICRORNA; BRAF PROTEIN, HUMAN; PARAFFIN;

ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; DIAGNOSTIC TEST ACCURACY STUDY; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; LYMPH NODE METASTASIS; METASTATIC MELANOMA; RNA EXTRACTION; COHORT ANALYSIS; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; MELANOMA; METABOLISM; MUTATION; PATHOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION; SKIN TUMOR; TREATMENT OUTCOME;

COHORT STUDIES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MELANOMA; MICRORNAS; MUTATION; NEOPLASM STAGING; PARAFFIN EMBEDDING; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; RNA, MESSENGER; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84927100405     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12343     Document Type: Article

References (50)

1. Almeida, M.I., Nicoloso, M.S., Zeng, L. et al. (2012). Strand-specific miR-28-5p and miR-28-3p have distinct effects in colorectal cancer cells. Gastroenterology 142, 886-896.e9.
2. Balch, C.M., Gershenwald, J.E., Soong, S.J. et al. (2009). Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27, 6199-6206.
3. Barbour, A.P., Tang, Y.H., Armour, N. et al. (2014). BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: Implications for melanoma staging and adjuvant therapy. Eur. J. Cancer 50, 2668-2676.
4. Bonazzi, V.F., Stark, M.S., and Hayward, N.K. (2012). MicroRNA regulation of melanoma progression. Melanoma Res. 22, 101-113.
5. Caramuta, S., Egyhazi, S., Rodolfo, M., Witten, D., Hansson, J., Larsson, C., and Lui, W.-O. (2010). MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. J. Invest. Dermatol. 130, 2062-2070.
6. Carter, C., De Silva, C., Synnott, M. et al. (2010). Bio-specimen banking: Melanoma Institute Australia (meeting abstract). Pigment Cell Melanoma Res. 23, 946-947.
7. Chan, E., Patel, R., Nallur, S. et al. (2011). MicroRNA signatures differentiate melanoma subtypes. Cell Cycle 10, 1845-1852.
8. Chen, J., Feilotter, H.E., Paré, G.C., Zhang, X., Pemberton, J.G.W., Garady, C., Lai, D., Yang, X., and Tron, V.A. (2010). MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma. Am. J. Pathol. 176, 2520-2529.
9. Chen, J.-S., Su, I.-J., Leu, Y.-W., Young, K.-C., and Sun, H.S. (2012). Expression of T-cell lymphoma invasion and metastasis 2 (TIAM2) promotes proliferation and invasion of liver cancer. Int. J. Cancer 130, 1302-1313.
10. Couts, K.L., Anderson, E.M., Gross, M.M., Sullivan, K., and Ahn, N.G. (2013). Oncogenic B-Raf signaling in melanoma cells controls a network of microRNAs with combinatorial functions. Oncogene 32, 1959-1970.
11. Crea, F., Clermont, P.L., Parolia, A., Wang, Y., and Helgason, C.D. (2014). The non-coding transcriptome as a dynamic regulator of cancer metastasis. Cancer Metastasis Rev. 33, 1-16.
12. Dawson, M.A., and Kouzarides, T. (2012). Cancer epigenetics: from mechanism to therapy. Cell 150, 12-27.
13. De Vries, E., and Willem Coebergh, J. (2004). Cutaneous malignant melanoma in Europe. Eur. J. Cancer 40, 2355-2366.
14. Flaherty, K.T., Infante, J.R., Daud, A. et al. (2012). Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations. N. Engl. J. Med. 367, 1694-1703.
15. Friedman, E., Shang, S., De Miera, E. et al. (2012). Serum microRNAs as biomarkers for recurrence in melanoma. J. Transl. Med. 10, 155.
16. Garbe, C., and Leiter, U. (2009). Melanoma epidemiology and trends. Clin. Dermatol. 27, 3-9.
17. Glud, M., Klausen, M., Gniadecki, R., Rossing, M., Hastrup, N., Nielsen, F.C., and Drzewiecki, K.T. (2009). MicroRNA expression in melanocytic nevi: the usefulness of formalin-fixed, paraffin-embedded material for miRNA microarray profiling. J. Invest. Dermatol. 129, 1219-1224.
18. Gould Rothberg, B.E., Bracken, M.B., and Rimm, D.L. (2009). Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J. Natl Cancer Inst. 101, 452-474.
19. Griffiths-Jones, S., Saini, H.K., Van Dongen, S., and Enright, A.J. (2008). miRBase: tools for microRNA genomics. Nucleic Acids Res. 36, D154-D158.
20. Grimson, A., Farh, K.K.-H., Johnston, W.K., Garrett-Engele, P., Lim, L.P., and Bartel, D.P. (2007). MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol. Cell 27, 91-105.
21. Guy, G.P.J., and Ekwueme, D.U. (2011). Years of potential life lost and indirect costs of melanoma and non-melanoma skin cancer: a systematic review of the literature. Pharmacoeconomics 29, 863-874.
22. Hodis, E., Watson, I.R., Kryukov, G.V. et al. (2012). A landscape of driver mutations in melanoma. Cell 150, 251-263.
23. Iwasaki, Y.W., Kiga, K., Kayo, H., Fukuda-Yuzawa, Y., Weise, J., Inada, T., Tomita, M., Ishihama, Y., and Fukao, T. (2013). Global microRNA elevation by inducible Exportin 5 regulates cell cycle entry. RNA 19, 490-497.
24. Jayaswal, V., Lutherborrow, M., Ma, D., and Yang, Y. (2011). Identification of microRNA-mRNA modules using microarray data. BMC Genom. 12, 138.
25. Jayawardana, K., Schramm, S.-J., Haydu, L., Thompson, J.F., Scolyer, R.A., Mann, G.J., Müller, S., and Yang, J.Y.H. (2014). Determination of prognosis in metastatic melanoma through integration of clinico-pathologic, mutation, mRNA, microRNA, and protein information. Int. J. Cancer 136, 863-874.
26. Kanehisa, M., Goto, S., Sato, Y., Furumichi, M., and Tanabe, M. (2012). KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res. 40, D109-D114.
27. Lee, Y., Ahn, C., Han, J., et al. (2003). The nuclear RNase III Drosha initiates MicroRNA processing. Nature 425, 415-419.
28. Lee, J.H., Choi, J.W., and Kim, Y.S. (2010). Frequencies of BRAF and NRAS mutations are different in histologic types and sites of origin of cutaneous melanoma: a meta-analysis. Br. J. Dermatol. 164, 776-784.
29. Leidinger, P., Keller, A., Borries, A., Reichrath, J., Rass, K., Jager, S.U., Lenhof, H.P., and Meese, E. (2010). High-throughput miRNA profiling of human melanoma blood samples. BMC Cancer 10, 262.
30. Levati, L., Alvino, E., Pagani, E. et al. (2009). Altered expression of selected microRNAs in melanoma: antiproliferative and proapoptotic activity of miRNA-155. Int. J. Oncol. 35, 393-400.
31. Lewis, B.P., Burge, C.B., and Bartel, D.P. (2005). Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are MicroRNA targets. Cell 120, 15-20.
32. Long, G.V., Menzies, A.M., Nagrial, A.M., Haydu, L.E., Hamilton, A.L., Mann, G.J., Hughes, T.M., Thompson, J.F., Scolyer, R.A., and Kefford, R.F. (2011). Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J. Clin. Oncol. 29, 1239-1246.
33. Lu, J., Getz, G., Miska, E.A. et al. (2005). MicroRNA expression profiles classify human cancers. Nature 435, 834-838.
34. Mann, G.J., Pupo, G.M., Campain, A.E. et al. (2013). BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. J. Invest. Dermatol. 133, 509-517.
35. Mcshane, L.M., Altman, D.G., Sauerbrei, W., Taube, S.E., Gion, M., and Clark, G.M. (2005). REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat. Clin. Pract. Onco. 2, 416-422.
36. Mueller, D.W., Rehli, M., and Bosserhoff, A.K. (2009). miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma. J. Invest. Dermatol. 129, 1740-1751.
37. Nguyen, T., Kuo, C., Nicholl, M.B., Sim, M.S., Turner, R.R., Morton, D.L., and Hoon, D.S. (2011). Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma. Epigenetics 6, 388-394.
38. Poliseno, L., Haimovic, A., Segura, M.F. et al. (2012). Histology-specific microRNA alterations in melanoma. J. Invest. Dermatol. 132, 1860-1868.
39. Richards, H.W., and Medrano, E.E. (2009). Epigenetic marks in melanoma. Pigment Cell Melanoma Res. 22, 14-29.
40. Satzger, I., Mattern, A., Kuettler, U., Weinspach, D., Voelker, B., Kapp, A., and Gutzmer, R. (2010). MicroRNA-15b represents an independent prognostic parameter and is correlated with tumor cell proliferation and apoptosis in malignant melanoma. Int. J. Cancer 126, 2553-2562.
41. Segura, M.F., Belitskaya-Levy, I., Rose, A.E. et al. (2010). Melanoma MicroRNA signature predicts post-recurrence survival. Clin. Cancer Res. 16, 1577-1586.
42. Segura, M.F., Greenwald, H.S., Hanniford, D., Osman, I., and Hernando, E. (2012). MicroRNA and cutaneous melanoma: from discovery to prognosis and therapy. Carcinogenesis 33, 1823-1832.
43. Selcuklu, S.D., Donoghue, M.T.A., Rehmet, K., De Souza Gomes, M., Fort, A., Kovvuru, P., Muniyappa, M.K., Kerin, M.J., Enright, A.J., and Spillane, C. (2012). MicroRNA-9 inhibition of cell proliferation and identification of novel miR-9 targets by transcriptome profiling in breast cancer cells. J. Biol. Chem. 287, 29516-29528.
44. Shiiyama, R., Fukushima, S., Jinnin, M. et al. (2013). Sensitive detection of melanoma metastasis using circulating microRNA expression profiles. Melanoma Res. 23, 366-372.
45. Slipicevic, A., and Herlyn, M. (2012). Narrowing the knowledge gaps for melanoma. Upsala J. Med. Sci. 117, 237-243.
46. Thompson, J.F., Scolyer, R.A., and Kefford, R.F. (2005). Cutaneous melanoma. Lancet 365, 687-701.
47. Tremante, E., Ginebri, A., Lo Monaco, E. et al. (2012). Melanoma molecular classes and prognosis in the postgenomic era. Lancet Oncol. 13, e205-e211.
48. Tucci, M.G., Lucarini, G., Brancorsini, D., Zizzi, A., Pugnaloni, A., Giacchetti, A., Ricotti, G., and Biagini, G. (2007). Involvement of E-cadherin, β-catenin, Cdc42 and CXCR4 in the progression and prognosis of cutaneous melanoma. Br. J. Dermatol. 157, 1212-1216.
49. Völler, D., Ott, C., and Bosserhoff, A. (2013). MicroRNAs in malignant melanoma. Clin. Biochem. 46, 909-917.
50. Whiteman, D.C., Pavan, W.J., and Bastian, B.C. (2011). The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res. 24, 879-897.